• Call +1.858.633.0165 or Fax +1.858.633.0166 or Contact Us

Sacubitrilat Inhibitor

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5764362

MBS5764362 is an inhibitor targeting Sacubitrilat. Sacubitrilat (LBQ657) is an effective inhibitor of active neprilysin (NEP). More details

Product Documentation
PDF
Sample Manual Insert View PDF
PDF
Testing Data View PDF
PDF
Certificate of Analysis (COA) View PDF
PDF
QC Report View PDF
PDF
Material Safety Data Sheet View PDF
PDF
Technical Datasheet View PDF
PDF
Protocol View PDF

Product Overview

Online Datasheet in PDF
Product Name
Sacubitrilat, Inhibitor
Full Product Name
Sacubitrilat
Product Synonym Names
LBQ-657
Form/Format
Solid. Powder
Purity/Purification
99.11%
Preparation and Storage
Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent
Molecular Weight
383.44
Solubility
DMSO: 100mg/mL (260.80mM)
(<1mg/ml refers to the product slightly soluble or insoluble)
Formula
C22H23NO5
SMILES
[H]N(C(CCC(O)=O)=O)[C@](CC(C=C1)=CC=C1C2=CC=CC=C2)C[C@](C(O)=O)C
CAS Number
149709-44-4
In Vitro
Pharmacokinetics of Sacubitril, Sacubitrilat, and valsartan following the administration of single oral doses of LCZ696 400 or 1200 mg under fasting conditions are summarized. The mean plasma concentrations of Sacubitril increases rapidly with a median Tmax of 0.52 h for the 400 mg dose and 1.05 h for the 1200 mg dose, followed by Sacubitrilat, with the corresponding Tmax values of 2.07 and 3.05 h, respectively. The median Tmax for valsartan is 2.07 h for both the LCZ696 400 mg and 1200 mg doses. The Cmax of Sacubitrilat shows a dose-proportional increase, while the Cmax of Sacubitril and Valsartan shows less than proportional increases between the doses [2].

Product References and Citations for Sacubitrilat, inhibitor

Schiering N, et al. Structure of neprilysin in complex with the active metabolite of sacubitril. Sci Rep. 2016 Jun 15;6:27909.
Schiering N, et al. Structure of neprilysin in complex with the active metabolite of sacubitril. Sci Rep. 2016 Jun 15;6:27909.
Langenickel TH, et al. Single therapeutic and supratherapeutic doses of sacubitril/valsartan (LCZ696) do not affect cardiac repolarization. Eur J Clin Pharmacol. 2016 Aug;72(8):917-24.
Langenickel TH, et al. Single therapeutic and supratherapeutic doses of sacubitril/valsartan (LCZ696) do not affect cardiac repolarization. Eur J Clin Pharmacol. 2016 Aug;72(8):917-24.

Other Notes

Small volumes of Sacubitrilat, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Request a Quote

Please fill out the form below and our representative will get back to you shortly.

MBS000000
Contact Us

Please fill out the form below and our representative will get back to you shortly.

MBS000000